Long-term study links infections to 70 percent higher dementia risk
By
Alicia Lasek
Jan 10, 2023
A study with 32 years of followup has linked infections in hospitalized patients to future dementia onset. Urinary tract infections are among those with the strongest link.
HHS halts Eli Lilly’s single-drug COVID antibody treatment in U.S.; dual-drug alternative remains in...
By
Alicia Lasek
Mar 26, 2021
U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...
Epilepsy raises risk of developing Alzheimer’s, and vice-versa
By
Alicia Lasek
May 29, 2023
People with a common type of epilepsy have nearly four times the relative odds of receiving an Alzheimer’s diagnosis, a new study finds.
FDA OKs third antibody COVID therapy; variants spur new pause on another
By
Alicia Lasek
Jun 01, 2021
A new COVID-19 treatment made by GlaxoSmithKline now is the third monoclonal antibody therapy federally authorized to help prevent severe disease outcomes in high-risk patients. But gene variants are interfering...
FDA to withdraw certain drug-related guidances with end of PHE
By
Alicia Lasek
Mar 14, 2023
The Food and Drug Administration has issued a notice detailing which COVID-19-related guidances will expire when the public health emergency ends as scheduled on May 11, and which guidances will remain...
Time from infection to COVID symptoms shortens with each new variant, study finds
By
Alicia Lasek
Aug 24, 2022
The average incubation period of SARS-CoV-2 has gradually shortened, from 5 days to 3.4. Determining incubation periods can help to pinpoint effective patient isolation periods, investigators say.
Clinical briefs for Wednesday, Dec. 1
By
Alicia Lasek
Dec 01, 2021
Regeneron’s COVID-19 antibody drug may be less effective against omicron, drugmaker says … Pandemic taking toll on healthcare workers’ sleep patterns … Ambulance staffing shortage frustrating nursing...
Feds halt an Eli Lilly antibody therapy in 3 states due to variant fears, while boosting the treatment...
By
Alicia Lasek
Mar 19, 2021
A COVID-19 variant circulating widely in California, Arizona and Nevada has rendered bamlanivimab alone ineffective, an FDA official reports. But Lilly says an approved alternative treatment “maintains...
Amyloid-busting drug for early Alzheimer’s fails to stop cognitive decline, long-term study concludes
By
Alicia Lasek (f3)
Jun 21, 2022
The failure of a more-than-decade-long trial in patients with early-onset Alzheimer’s deals yet another blow to a key treatment theory, observers say.
ADHD linked to Alzheimer’s disease across generations, scientists say
By
Alicia Lasek
Sep 14, 2021
Parents of children diagnosed with attention deficit hyperactivity disorder are more likely to receive a diagnosis of Alzheimer’s than their peers whose children do not have the condition, investigators...